Connection

Mitzi Nagarkatti to Autoimmune Diseases

This is a "connection" page, showing publications Mitzi Nagarkatti has written about Autoimmune Diseases.
Connection Strength

0.530
  1. Combined deficiency in CD44 and Fas leads to exacerbation of lymphoproliferative and autoimmune disease. Int Immunol. 2003 Nov; 15(11):1327-40.
    View in: PubMed
    Score: 0.200
  2. Epigenetic Regulation of Cannabinoid-Mediated Attenuation of Inflammation and Its Impact on the Use of Cannabinoids to Treat Autoimmune Diseases. Int J Mol Sci. 2021 Jul 07; 22(14).
    View in: PubMed
    Score: 0.170
  3. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009 Oct; 1(7):1333-49.
    View in: PubMed
    Score: 0.075
  4. The emerging role of leptin antagonist as potential therapeutic option for inflammatory bowel disease. Int Rev Immunol. 2014 Jan; 33(1):23-33.
    View in: PubMed
    Score: 0.024
  5. CD4-CD8- thymocytes from MRL-lpr/lpr mice exhibit abnormal proportions of alpha beta- and gamma delta-TCR+ cells and demonstrate defective responsiveness when activated through the TCR. Cell Immunol. 1991 Oct 15; 137(2):269-82.
    View in: PubMed
    Score: 0.022
  6. Evidence for major alterations in the thymocyte subpopulations in murine models of autoimmune diseases. J Autoimmun. 1990 Jun; 3(3):271-88.
    View in: PubMed
    Score: 0.020
  7. Evidence for the existence of distinct heterogeneity among the peripheral CD4-CD8- T cells from MRL-lpr/lpr mice based on the expression of the J11d marker, activation requirements, and functional properties. Cell Immunol. 1990 May; 127(2):442-57.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.